The host genetic basis of mixed cryoglobulin vasculitis is not well understood and has not been studied in large cohorts. A genomewide association study was conducted among 356 hepatitis C virus (HCV) RNA-positive individuals with cryoglobulin-related vasculitis and 447 ethnically matched, HCV RNA-positive controls. All cases had both serum cryoglobulins and a vasculitis syndrome. A total of 899 641 markers from the Illumina HumanOmni1-Quad chip were analyzed using logistic regression adjusted for sex, as well as genetically determined ancestry. Replication of select single-nucleotide polymorphisms (SNPs) was conducted using 91 cases and 180 controls, adjusting for sex and country of origin. The most significant associations were identified on chromosome 6 near the NOTCH4 and MHC class II genes. A genome-wide significant association was detected on chromosome 6 at SNP rs9461776 (odds ratio ¼ 2.16, P ¼ 1.16E À 07) between HLA-DRB1 and DQA1: this association was further replicated in additional independent samples (meta-analysis P ¼ 7.1 Â 10
INTRODUCTION
More than 185 million individuals have been exposed to hepatitis C virus (HCV) and an estimated 130 million have chronic infection. 1 Although the main target of this virus is the hepatocyte, HCV also appears to infect lymphocytes. 2 Patients with chronic HCV infection typically produce anti-HCV immunoglobulin G and can develop not only hepatic disease but also extrahepatic conditions among which the most frequent is mixed cryoglobulinemia (MC). 3, 4 MC vasculitis is both an autoimmune and B-lymphoproliferative disorder, clinically benign, but evolving in 8-10% of cases into a frank non-Hodgkin's lymphoma. 5 Cryoglobulins are called 'mixed' because they are composed of both immunoglobulin G and immunoglobulin M that can be partially monoclonal (type II MC) or totally polyclonal (type III MC) and have rheumatoid factor activity. [6] [7] [8] The prefix 'cryo' refers to the property that these immune complexes precipitate at temperatures below 37 1C and dissolve with rewarming. 9 Approximately half of individuals with chronic HCV infection have serum cryoglobulins, but only B5% develop a clinically evident MC vasculitis syndrome. 10, 11 This HCV-related cryoglobulinemic vasculitis most commonly manifests in the skin (palpable purpura, 80%), joints (70%), peripheral nerves (60%) and kidney (immune complex nephritis, 20%). 11 Because of the wide range of symptoms, MC vasculitis subjects are often clinically referred to different specialties, and thus the actual prevalence may be underestimated. 10 The clinical vasculitis syndrome can be improved or resolved by therapy directed at HCV infection and/or the B-cell proliferation (for example, with rituximab), inflammation (for example, with corticosteroids) or serum cryogolbulins (for example, with plasmapheresis). [12] [13] [14] [15] [16] [17] Although the pathogenesis of the MC vasculitis syndrome is still unclear, accumulating evidence points to a role for host genetics. There are no consistent differences in the infecting viruses of individuals with chronic infection with or without the vasculitis syndrome. 4, 18 There are marked ethnic and regional differences in the prevalence of MC vasculitis, with the highest prevalence in individuals of Mediterranean descent. 10, [19] [20] [21] Pozzato et al. 22 found only Mediterranean descent explained the much higher prevalence of MC vasculitis in Italy compared with Japan. In addition, several studies have identified associations between MC vasculitis and particular human leukocyte antigen (HLA) alleles. [23] [24] [25] [26] [27] The purpose of this investigation was to perform a genome-wide, multicenter study to investigate the host genetic basis for MC vasculitis in individuals with chronic HCV infection.
RESULTS
We identified 356 individuals with cryoglobulin-related vasculitis and chronic HCV infection. A total of 447 controls with chronic HCV infection but with no cryoglobulin-related vasculitis were selected from a previously published genome-wide association study (GWAS) of spontaneous clearance versus chronic infection of HCV, or were specifically screened for this study. 28 After quality control measures, 899 641 single-nucleotide polymorphisms (SNPs) were compared between cases and controls.
The most significant association was located on chromosome 6p21.32 ( Figure 1 and Table 1 ). A SNP, rs2071286, located within an intronic region of NOTCH4 (P ¼ 6.2 Â 10 À 9 ) conferred 2.15 times the odds of having cryoglobulin-related vasculitis within chronically infected patients for each risk allele. An additional SNP within NOTCH4 at rs2071279 (P ¼ 1.6 Â 10 À 7 ) had a similar effect size with each risk allele (T) resulting in 1.90 times the odds of disease. To confirm these findings, replication was attempted for both of these SNPs; however, rs2071286 did not reach significance (P ¼ 0.13) and rs2071279 failed in production. In addition, the next most significant NOTCH4 findings (rs9267820 and rs9267833) also did not meet the replication threshold (P40.01; Table 2 ).
The second most significant association was found nearly 400 kb away within the major histocompatibility complex (MHC) between HLA-DRB1 and HLA-DQA1 at SNP rs9461776 (P ¼ 1.2 Â 10 À 7
). Each additional copy of the risk allele (G) was associated with 2.16 times the odds of cryoglobulin-related vasculitis. This SNP was significantly replicated in an independent sample of cases and controls (P ¼ 0.01). When the discovery and replication stages were combined within a meta-analysis, rs9461776 had a P-value of 7.1 Â 10 À 9 (odds ratio ¼ 2.02, I 2 ¼ 0). Imputation of additional SNPs in both the NOTCH4 and MHC regions areas did not yield more significant signals than the actual genotyped SNPs, and this may reflect the strong linkage disequilibrium (LD) in the region.
The LD structure around the top NOTCH4 association ( Figure 2 ) suggests that there are two distinct blocks of LD defining NOTCH4 and the MHC region. However, rs2071286 and rs2071279 in NOTCH4 are in strong LD (D' ¼ 0.98, Figure 2 ) and both are in LD with the HLA class II SNP rs9461776 (D 0 ¼ 0.71 and 0.73, respectively) despite low r 2 values, likely because of differences in minor allele frequencies ( Figure 2 ). To determine whether the two regions might be statistically representing the same underlying association, we performed a conditional analysis. The associations in this region were conditioned on the NOTCH4 SNP, rs2071286, and the other associations in this region were attenuated to Po10 À 4 ( Figure 3 ). When the associations were conditioned on the top HLA class II SNP, rs9461776, the other associations in the region were also attenuated to Po10 À 4 . These results do not clarify whether the underlying causal allele in this region is attributable to NOTCH4 or to the HLA class II alleles.
DISCUSSION
In this investigation we found strong evidence of a host genetic basis for MC vasculitis focused in and around the MHC class II and NOTCH4 genes. Although there have been reported associations of MC vasculitis with the class II MHC region, the findings have been inconsistent. Cacoub et al. 27 found an association of the HLA class II allele DRB1*11 with HCV-related cryoglobulinemia, although Amoroso et al. 26 failed to find a significant association with HLA DR or DQ loci. In a separate study by De Re et al.,
29 DR5 and DQ3 alleles were associated with HCV-related cryoglobulinemic vasculitis. In a study of 25 HCV-positive MC vasculitis patients and 407 controls, Lenzi et al. 24 suggested an HLA-B8-DR3 haplotype associated with susceptibility to MC vasculitis, partially confirmed by a Chinese report. 23 The complexity of the MHC region, the ethnic differences in populations and the smaller sample sizes in the earlier studies may also contribute to the differences in association results. In this GWAS of European individuals, we do identify a significant association in the extended HLA class II region that is independent of the recently associated HLA Class II HCV viral clearance region. 28 However, the nearby NOTCH4 gene also shows association with MC vasculitis in the current study. The Notch proteins are a family of transmembrane proteins (Notch 1-4) that serve as receptors for a signal transduction pathway. The Notch genes are involved with promotion and inhibition of cell differentiation and gene expression in a positive feedback loop. Genome-wide associations have shown significant associations of NOTCH4 with systemic sclerosis, myeloperoxidase levels, age-related macular degeneration, asthma and schizophrenia. 30, 31 In addition, independently of HLA genes, NOTCH4 polymorphisms have been associated with autoimmune disorders. 32, 33 The importance of Notch signaling in T-cell development makes it a viable candidate gene for MC vasculitis. However, the SNPs that mark NOTCH4 and MHC class II are too strongly correlated to discriminate the degree to which each region contributes to the association, and there is no tractable experimental model of MC vasculitis that can be used to dissect the association further.
In summary, our GWAS data based on a large sample of MC vasculitis patients and controls identified two significant regions with implicated polymorphisms: MHC Class II and NOTCH4. However, we do not have evidence to indicate the causal variants for these associations. Each of these genes may play a role but further investigation is needed to determine the biologic link to this syndrome. 
MATERIALS AND METHODS Subjects
The case participants in both the discovery and replication stages were enrolled in nine different studies using study-specific case definitions (Supplementary Methods and Supplementary Table 1 28 The research was approved by the relevant institutional review boards for each study.
Genotyping
In the initial analysis, 3454 individuals were genotyped on the Illumina (San Diego, CA, USA) Human Omni-Quad array at the Center for Inherited Disease Research. Samples included both cases and controls who were recruited specifically for MC vasculitis (N ¼ 497), as well as a previously published GWAS for spontaneous HCV resolution versus chronic infection (N ¼ 2957). A total of 1 134 514 SNPs were released with genotype and intensity data. Standard quality control measures were performed for both the individual and SNP. Individuals were excluded if the percentage of missing data was 42% and/or individuals were more related than expected (first-degree relatives). Markers were excluded if the percentage of missing genotypes was 45%, the minor allele frequency was o1% or there were strong deviations from Hardy-Weinberg equilibrium (P410 À 5 ). Principal components analysis was used to determine genetic ancestry using 41 871 autosomal-independent SNPs, excluding regions known to be associated with ethnicity, such as the extended HLA region and the lactase gene. Only individuals who clustered with European ancestry were included in further analyses (N ¼ 983). Within individuals of European descent, a gradient was apparent from the United Kingdom to Italy, with the French participants clustering in the middle (Supplementary Figures 1A  and B) . This is consistent with prior studies showing a North-South ancestral cline in Europe. 34 The association between the principal components (PCs) and outcome was statistically significant for only the first two PCs (Po0.05), and therefore both PCs were included in all genome-wide analyses. The inflation factor (l) after adjusting for the first two PCs and sex was 0.97, suggesting there was no genomic inflation due to confounding (Supplementary Figure 2) . The final genome-wide data set included 983 individuals (356 cases and 627 controls) at 899 641 locations across the genome.
Statistical analysis
The initial analysis was the discovery phase and included cryoglobulinemia-associated vasculitis cases (n ¼ 356) and the HCV GWAS controls (n ¼ 447) with similar ancestral clustering (principal components analysis determined) and chronic HCV infection from eight different studies (Toulouse Cohort, BAHSTION, RomeCryo, Mangia, REVELL, Cacoub (Paris VIREP-C Study), the UK Drug Cohort and MASVE). The controls consisted of individuals with chronic HCV infection from the HCV GWAS (N ¼ 355), as well as a set of controls recruited specifically for this study (N ¼ 92). These latter were consecutively recruited patients with chronic HCV infection showing complete absence of features of MC vasculitis or other autoimmune and/or lymphoproliferative disorders (that is, purpura, arthralgia, asthenia, polyneuropathy, nephritis, sicca syndrome, cryoglobulinemia, rheumatoid factor activity, complement consumption, autoantibodies and monoclonality) confirmed during at least 2 years of follow-up in two yearly evaluations. All tests of association were conducted in the statistical software Plink. 35 GWAS was performed using logistic regression, under an additive genetic model adjusting for the first two PCs and sex. A significance threshold of Po5 Â 10 À 7 was used to assess genome-wide significance. 36 The À log 10 P-values from each SNP logistic regression was plotted to generate a Manhattan plot (Figure 1) . A conditional analysis was conducted using the top-associated SNPs (rs2071286, rs9461776) by adding the SNP as a covariate to the logistic regression and evaluating the association. Imputation SNP imputation was conducted to increase the density of untyped markers around significant and suggestive association signals using the statistical program IMPUTE2, 37 using a multiethnic reference panel from four continents (Africa, North and South America, Asia and Europe) as part of the 1000 Genomes Project. 38 The imputed genotypes were analyzed using logistic regression under an additive model adjusting for the first two PCs and sex. An Expectation-Maximization algorithm was used to incorporate the probabilities of each genotype in the logistic regression.
Replication
To confirm the novel findings from the discovery phase of the GWAS, a replication study was performed using convenience samples for the cases and a subset of controls with chronic HCV from the previously published GWAS. Controls were selected to be matched 2:1 with the cases based on their study's country of origin (Table 1 ). SNPs were genotyped that had reached either genome-wide significance (Po5 Â 10 À 7 ) or were SNPs in LD with the genome-wide significant SNPs and had suggestive P-values (Po5 Â 10 À 6 ). A total of 4 SNPs were analyzed for replication in 92 cases and 179 controls from 7 study sites including one new site not represented in the discovery stage (Toulouse Cohort, BAHSTION, Charles, RomeCryo, Mangia, Cacoub (Paris VIREP-C Study) and MASVE). Using the standard Qiagen spin protocol, DNA for genotyping was extracted from stored cells using the QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA). Genotyping for SNPs was performed with TaqMan SNP genotyping assays (Life Technologies, Carlsbad, CA, USA) that use unique primers and probes sets to target each polymorphism. Taqman's standard protocol for 5.0 ml reactions was utilized. The Roche LightCycler 480 Real-Time System (Roche Applied Science, Indianapolis, IN, USA) was used to amplify the DNA and measure the fluorescence from each reaction to determine the genotype using Roche's Endpoint Genotyping Software.
Tests of association were conducted in Plink using logistic regression, adjusted for study country of origin and sex. A conventional P-value threshold was used for replication (Pp0.01). A meta-analysis was conducted between the discovery and replication associations using a fixed effects model in META 39, 40 and evaluated for heterogeneity (I   2   ) . LD was estimated in Haploview. 41 
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